within Pharmacolibrary.Drugs.ATC.D;

model D07AB02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.02,
    Cl             = 20 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,
    adminCount     = 1,
    Vd             = 0.04,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Hydrocortisone butyrate is a topical corticosteroid used primarily for its anti-inflammatory, antipruritic, and vasoconstrictive properties to treat skin conditions such as eczema, dermatitis, allergies, and rash. It is available both by prescription and over-the-counter in several countries and remains an approved medication for dermatological use.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic parameters for hydrocortisone butyrate in humans were found. Parameters below are estimated based on general corticosteroid PK, primarily for topical administration in adults.</p><h4>References</h4><ol><li><p>Brogden, RN, Pinder, RM, Sawyer, PR, Speight, TM, &amp; Avery, GS (1976). Hydrocortisone 17-butyrate: a new topical corticosteroid preliminary report. <i>Drugs</i> 12(4) 249–257. DOI:<a href=&quot;https://doi.org/10.2165/00003495-197612040-00001&quot;>10.2165/00003495-197612040-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/786608/&quot;>https://pubmed.ncbi.nlm.nih.gov/786608</a></p></li><li><p>Yang, X, Trinh, HM, Agrahari, V, Sheng, Y, Pal, D, &amp; Mitra, AK (2016). Nanoparticle-Based Topical Ophthalmic Gel Formulation for Sustained Release of Hydrocortisone Butyrate. <i>AAPS PharmSciTech</i> 17(2) 294–306. DOI:<a href=&quot;https://doi.org/10.1208/s12249-015-0354-5&quot;>10.1208/s12249-015-0354-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26085051/&quot;>https://pubmed.ncbi.nlm.nih.gov/26085051</a></p></li><li><p>Barry, BW (1976). Bioavailability of topical steroids. <i>Dermatologica</i> 152 Suppl 1 47–65. DOI:<a href=&quot;https://doi.org/10.1159/000257866&quot;>10.1159/000257866</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/955238/&quot;>https://pubmed.ncbi.nlm.nih.gov/955238</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D07AB02;
